Maven Securities’s NextCure NXTC Stock Holding History

Maven Securities’s Portfolio NXTC Stock Details NXTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q1	–	Sell	-833	Closed	-$535K	–	399
2019 Q4	$535K	Buy	+833	New	+$418K	0.05%	250

Other funds holding NXTC

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

CPX

Canaan Partners X Menlo Park, California $74.7M AUM 151.56% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Maven Securities's NXTC Position: Q1 2020 in Review

Maven Securities sold out of NextCure (NXTC) in Q1 2020, closing a stake of 833 shares — an estimated $535K sold.

Maven Securities first reported a position in NXTC in Q4 2019 and held it in 1 quarter. The position peaked at $535K in Q4 2019. 82 funds tracked by Wall St. Rank hold NXTC as of Q1 2020.

Maven Securities reported no remaining NextCure position as of Q1 2020 after selling out during the quarter.
Maven Securities sold 833 NextCure shares in Q1 2020, an estimated $535K.
Maven Securities first reported a position in NextCure in Q4 2019 and held it in 1 quarter.
Maven Securities's NextCure position peaked at $535K in Q4 2019.
82 funds tracked by Wall St. Rank held NextCure as of Q1 2020.

Based on Maven Securities's 13F filing for Q1 2020, filed 15 May 2020.